Received Jul 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | UNK | — |
My 17 year old daughter received one dose on June 23 and the second dose today on July 7; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of drug dose administration interval too short in a 17-year-old female patient who received Men B NVS (Bexsero) for prophylaxis. Concomitant products included Meningococcal vaccine B rfHbp/NadA/NHBA OMV (Bexsero). On 07-JUL-2025, the patient received the 2nd dose of Bexsero. On 07-JUL-2025, an unknown time after receiving Bexsero, the patient experienced drug dose administration interval too short (Verbatim: My 17 year old daughter received one dose on June 23 and the second dose today on July 7). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 07-JUL-2025 The reporter reported that the patient received one dose of Bexsero vaccine on June 23 and the second dose today on July 7 as directed by our provider, which led to drug dose administration interval too short. The reporter was ask this was correct dosage, according to what reporter seeing on the site it looks like it should have been 6 months apart.